Injection-Site Sarcoma in Cats: Signs, the 3-2-1 Rule, Treatment and Prevention

Injection-Site Sarcoma in Cats: Signs, the 3-2-1 Rule, Treatment and Prevention

By Dr Duncan Houston

Finding a lump after your cat has received a vaccination or another injection is understandably worrying. The reassuring news is that most temporary injection-site swellings are inflammatory reactions rather than cancer.

Feline injection-site sarcoma is rare, but it must be taken seriously because it grows deeply into surrounding muscle and connective tissue. A small visible lump may have microscopic extensions far beyond what can be felt from the outside.

This is also one cancer where the first operation matters enormously. Removing the lump casually without imaging or appropriate margins can make later treatment more difficult and reduce the chance of long-term control.

Quick Answer

Feline injection-site sarcoma is a rare, locally aggressive cancer that develops at or near a previous injection site. Vaccines are the best-known association, but other injected medications and chronic inflammatory sites have also been implicated.

Use the 3-2-1 rule for any post-injection lump. It should be investigated with an incisional biopsy if it remains for three months, measures more than 2 cm, or is still increasing in size one month after the injection. Suspicious lumps should not simply be removed as a routine lumpectomy. Proper biopsy, CT or MRI staging and oncological surgical planning should come first.

What Is Feline Injection-Site Sarcoma?

Feline injection-site sarcoma, commonly shortened to FISS, is a malignant tumour arising within the skin, subcutaneous tissue, fascia or muscle at a previous injection site.

Most are fibrosarcomas, but other mesenchymal tumours can occur.

FISS is characterised by:

• Deep local invasion

• Irregular microscopic extensions into surrounding tissue

• A high risk of local recurrence after inadequate surgery

• A meaningful risk of spread to the lungs or other sites

• The need for substantially wider surgery than the visible lump suggests

The term injection-site sarcoma is more accurate than “vaccine-associated sarcoma” because vaccines are not the only injections linked with this disease. Sarcomas have also been reported after other medications and at sites of prolonged subcutaneous inflammation.

How Common Is Injection-Site Sarcoma?

FISS is rare.

A 2026 systematic review and meta-analysis examined more than 14 million feline vaccinations and identified a pooled estimate of approximately 8.8 sarcomas per 100,000 vaccinations. That is roughly one case per 10,000 vaccinations.

However, estimates varied widely between studies, and the certainty of the evidence was rated very low because surveillance, reporting and study methods were inconsistent. The real incidence may therefore differ between populations and vaccine programmes.

The practical message is:

• The complication is serious

• The absolute risk is low

• Vaccination should not be abandoned

• Vaccination decisions should be individualised

• Injection location and post-injection monitoring matter

The risk from preventable infectious disease is usually much greater than the risk of FISS in a cat for whom vaccination is medically indicated.

What Causes Injection-Site Sarcoma?

The exact mechanism has not been completely established.

The leading theory is that persistent inflammation at an injection site creates an environment in which susceptible connective-tissue cells undergo malignant transformation.

The process probably involves several factors:

• Local inflammation

• Tissue repair and fibroblast proliferation

• Accumulated DNA damage

• Individual genetic susceptibility

• Characteristics of the injected product

• The duration and severity of the inflammatory response

Most cats experience injections without developing cancer. Even cats that develop a temporary inflammatory lump almost always recover without a sarcoma forming.

FISS is therefore not simply the result of an injection being “done incorrectly”. It appears to require an unusual interaction between inflammation and the individual cat’s biology.

Are Adjuvanted Vaccines More Likely to Cause Sarcoma?

Possibly, but the evidence is not strong enough to declare one vaccine type completely safe or another automatically dangerous.

Adjuvants are substances used in some vaccine formulations to strengthen the immune response. Because adjuvanted vaccines may produce more local inflammation, they have long been suspected of carrying a higher FISS risk.

Some observational evidence suggests that non-adjuvanted or recombinant vaccines may be associated with a lower risk. However, current AAHA/AAFP guidance considers the evidence insufficient to recommend one vaccine formulation universally on FISS risk alone.

No injectable vaccine can currently be considered risk-free. Vaccine selection should consider:

• The disease being prevented

• The cat’s exposure risk

• Duration of immunity

• Licensing requirements

• Previous vaccine reactions

• Available formulations

• The individual cat’s health

• The injection location

Where clinically equivalent options exist, discussing a non-adjuvanted or recombinant formulation is reasonable. It should not replace appropriate vaccination intervals, site selection and monitoring.

Can Other Injections Cause FISS?

Yes.

Vaccines are the most commonly recognised association, but sarcomas have also been reported after:

• Long-acting injectable medications

• Corticosteroid injections

• Antibiotic injections

• Non-steroidal anti-inflammatory injections

• Other products causing local inflammation

• Subcutaneous access devices or fluid ports

These reports do not mean that a cat should be denied medically necessary injections. They reinforce the principle that unnecessary injections should be avoided and that all injectable products should be administered at a documented, surgically appropriate site whenever possible.

What Does an Injection-Site Sarcoma Feel Like?

A FISS may feel:

• Firm

• Irregular

• Deep beneath the skin

• Fixed to muscle or underlying tissue

• Poorly movable

• Painless initially

• Progressively larger

• More extensive than it first appears

As the tumour advances, it may become:

• Painful

• Ulcerated

• Bleeding

• Infected

• Attached to bone

• Restrictive to limb or shoulder movement

• Large enough to interfere with resting or grooming

The lump may initially seem small and well-defined. Unfortunately, the palpable edge is not necessarily the biological edge of the cancer.

Are All Lumps After Vaccination Cancer?

No.

Small inflammatory reactions can occur after vaccination or medication. These may feel soft or firm and often shrink over the following days or weeks.

A routine injection reaction is more likely to be:

• Small

• Mildly tender

• Freely movable

• Stable or decreasing in size

• Unaccompanied by skin ulceration

• Resolving over time

A suspicious mass is more likely to be:

• Growing

• Larger than 2 cm

• Still present after three months

• Deep or fixed

• Irregular

• Painful

• Ulcerated

• Bleeding

• Associated with reduced movement

Appearance and texture alone cannot confirm or exclude sarcoma. The behaviour of the lump over time is critical.

What Is the 3-2-1 Rule?

The 3-2-1 rule identifies post-injection masses that need biopsy.

Arrange further investigation if the mass:

• Remains present for 3 months after the injection

• Measures more than 2 cm across

• Is increasing in size 1 month after the injection

Meeting any one of these criteria is enough to justify an incisional biopsy. The cat does not need to meet all three.

The rule is not permission to ignore an aggressive lump

Do not wait three months when a mass is:

• Growing rapidly

• Already more than 2 cm

• Fixed to underlying tissue

• Painful

• Ulcerated

• Bleeding

• Associated with reduced limb movement

• Clinically unusual in any other way

A clearly concerning mass should be assessed promptly, regardless of how recently the injection was given.

What if you do not know when the injection was given?

Treat any clearly enlarging or persistent mass near a common injection site as suspicious.

Ask the veterinary clinic for:

• Vaccination records

• Medication records

• Exact administration sites

• Dates

• Product names

• Routes of administration

Even when no injection is documented, a feline soft-tissue mass still requires investigation.

How Worried Should You Be?

Risk level	What you may notice	Recommended action
Low risk	Small post-injection swelling that is soft or mildly firm and clearly shrinking	Photograph and measure it. Continue monitoring
Moderate concern	Lump remains several weeks later but is under 2 cm, stable and not painful	Arrange a routine veterinary recheck rather than assuming it will disappear
High concern	Mass meets any part of the 3-2-1 rule, is firm, fixed, irregular or growing	Arrange an incisional biopsy and oncological diagnostic plan promptly
Severe	Rapid growth, ulceration, bleeding, pain, reduced limb movement or recurrent mass after previous removal	Seek same-day or next-day veterinary assessment and referral
Critical	Uncontrolled bleeding, severe pain, inability to walk, collapse, marked breathing difficulty or profound deterioration	Go to an emergency veterinary hospital immediately

A small, stable lump is usually not a midnight emergency. It is still time-sensitive if it fails to resolve.

What Else Can Cause a Lump at an Injection Site?

Important differential diagnoses include:

Temporary inflammatory reaction

This is the most common explanation for a small lump appearing soon after vaccination. It should progressively shrink.

Granuloma

A granuloma is an organised inflammatory response that can remain firmer or persist longer than a simple swelling. Persistent granulomas still need assessment because they can resemble a tumour.

Abscess

An abscess may be:

• Painful

• Warm

• Soft or fluctuant

• Associated with fever

• Accompanied by discharge

• Increasing quickly

Seroma or haematoma

A fluid or blood-filled swelling may develop after tissue trauma. These are usually softer and more mobile than a sarcoma.

Cyst

Skin and subcutaneous cysts can develop near injection sites by coincidence.

Non-injection-site sarcoma

A sarcoma may arise without any relationship to vaccination or medication.

Other tumours

Possibilities include:

• Mast cell tumour

• Peripheral nerve sheath tumour

• Lymphoma

• Histiocytic tumour

• Bone tumour

• Metastatic cancer

• Other soft-tissue neoplasia

The location and timing raise or lower suspicion, but only tissue diagnosis establishes what the lump actually is.

How Do Vets Diagnose Injection-Site Sarcoma?

A proper investigation should answer four questions:

1. Is this a sarcoma?

2. How far has it extended locally?

3. Has it spread elsewhere?

4. Can it be removed with adequate margins?

1. Review the Injection History

The veterinary team should establish:

• When the mass was first noticed

• How quickly it is growing

• Which injections were previously given

• Where each injection was administered

• Whether the mass has already been sampled or removed

• Whether it has recurred

• Whether the cat has pain or mobility changes

The mass should be measured in three dimensions and its relationship with muscle, bone and the skin documented.

Photographs help establish whether the tumour is changing between visits.

2. Incisional Biopsy

An incisional biopsy removes a representative portion of the mass while leaving the main tumour in place for definitive treatment planning.

This is usually preferred when FISS is suspected.

The biopsy:

• Confirms whether the mass is malignant

• Helps identify the sarcoma subtype

• Provides information about tumour grade

• Allows definitive surgery or radiation to be planned properly

The biopsy incision and tract must be positioned so they can be completely removed during later surgery. Contaminating additional tissue planes can unnecessarily enlarge the final surgical field.

Why is fine-needle aspiration not enough?

Fine-needle aspiration may occasionally identify malignant cells or another diagnosis, but FISS often releases few diagnostic cells.

A nondiagnostic aspirate does not rule out sarcoma.

AAHA/AAFP guidance specifically warns that fine-needle aspirates may not provide adequate diagnostic tissue in these masses.

Why not remove the entire lump as the biopsy?

An unplanned excisional biopsy usually removes only the visible lump.

FISS requires margins that may extend:

• 5 cm around the mass

• Two fascial planes beneath it

• Through involved muscle

• Around the complete biopsy tract

• Into adjacent bone when necessary

A routine excision rarely achieves this.

It may leave tumour cells behind, contaminate tissue planes, create scar tissue and make the eventual definitive surgery larger and more difficult.

3. CT or MRI

Cross-sectional imaging is strongly recommended before definitive surgery or radiation therapy.

CT or MRI can assess:

• Tumour depth

• Muscle involvement

• Contact with bone

• Chest or abdominal wall involvement

• Relationship with the spine or shoulder blades

• Number of tissue compartments involved

• Potential surgical margins

• Radiation treatment volume

FISS frequently has irregular projections extending from the central mass. Imaging helps reveal disease that cannot be identified by palpation alone.

Neither CT nor MRI can determine with certainty whether every nearby abnormal-looking area contains cancer. Imaging is used to plan an appropriately aggressive treatment field, not to identify every microscopic tumour cell.

The sequence of biopsy and imaging should be planned with the surgeon or oncologist. Previous surgery or biopsy can alter the appearance of the tissues and complicate interpretation.

4. Staging for Metastasis

Staging may include:

• Three-view chest radiographs

• Thoracic CT

• Regional lymph node assessment

• Abdominal ultrasound in selected cats

• Complete blood count

• Serum biochemistry

• Urinalysis

The lungs are an important metastatic site.

Published metastatic rates vary, but approximately 10% to 28% of cats develop detectable spread in many reported populations. The risk is higher with high-grade, recurrent or biologically aggressive tumours.

Normal chest imaging does not guarantee that microscopic metastases are absent. It means no detectable spread was identified at that time.

5. Histopathology and Tumour Grade

The pathology report should ideally include:

• Exact tumour type

• Histological grade

• Mitotic count or proliferation information

• Necrosis

• Invasion

• Lymphovascular involvement

• Surgical margin measurements

• Identification of the closest or incomplete margin

Tumour grade and mitotic activity help estimate the risk of recurrence and metastasis.

All tissue removed during definitive surgery should be submitted for histopathology and margin analysis. A report of complete margins is reassuring but cannot guarantee that every tumour cell has been removed because only representative sections of the specimen can be examined.

What Is the Best Treatment?

For a resectable FISS, the strongest treatment usually begins with radical oncological surgery.

Radiation therapy may be added before or after surgery, depending on tumour location, size, margins and previous treatment.

Chemotherapy may also be discussed in cats with high-grade disease, metastasis, recurrent tumours or other high-risk features.

Why the First Surgery Matters So Much

The first definitive surgery offers the best opportunity to remove the tumour before:

• Scar tissue obscures normal tissue planes

• Cancer cells are dispersed through a larger field

• The mass becomes larger

• Important structures become involved

• Multiple satellite recurrences develop

Cats treated after only one properly planned surgery generally have better disease control than cats referred after repeated marginal excisions.

A “quick lump removal” can therefore be the least conservative option if it sacrifices the only realistic opportunity for clean margins. Studies of cats receiving surgery and radiation have consistently found worse disease control after multiple previous operations.

How Wide Does Surgery Need to Be?

Current AAHA oncology guidance recommends removing feline injection-site sarcomas with:

• 5 cm lateral margins

• Two complete fascial planes beneath the tumour

The biopsy scar and any contaminated tissue must also be removed.

This may require removing:

• One or more complete muscles

• Sections of abdominal or chest wall

• Part of a shoulder blade

• Dorsal spinal processes

• Ribs

• Part of the pelvis

• An entire limb

• A section of the tail

The operation can look disproportionate to the original lump. That is because the surgeon is treating the tumour’s biological reach rather than merely its visible outline.

When Is Amputation Recommended?

Amputation may offer the best chance of clean margins when the tumour is located on a distal limb.

Depending on the location, treatment may involve:

• Forelimb amputation

• Hindlimb amputation

• Hemipelvectomy for proximal pelvic-limb involvement

• Tail amputation for a distal tail tumour

Cats usually adapt well to limb amputation when their remaining limbs, neurological function and general health are suitable.

This is one reason feline vaccinations are recommended in distal limbs or the distal tail. If a tumour develops, amputation can provide a realistic path to radical removal.

How Effective Is Radical Surgery?

Results vary substantially according to:

• Margin width

• Tumour size

• Location

• Whether this is the first surgery

• Histological grade

• Surgeon experience

• Metastatic disease

• Use of additional treatment

In a study of 91 cats treated with radical 5 cm-margin excision:

• Local recurrence occurred in 14%

• Metastasis was identified in 20%

• Median overall survival was 901 days

• Cats without recurrence had a median survival of 1,461 days

• Cats without metastasis had a median survival of 1,528 days

These results came from cats selected for extremely aggressive surgery and should not be promised to every patient. They demonstrate how much better local control can be when the first procedure is genuinely radical.

Broader clinical populations report much higher recurrence rates, particularly after smaller or incomplete operations. Current AAHA oncology guidance describes FISS as having a high overall risk of local recurrence and emphasises that radical surgery offers the best chance of surgical cure.

When Is Radiation Therapy Used?

Radiation therapy may be used:

• Before surgery

• After surgery

• For an incompletely removed tumour

• When the margins are narrow

• When gross disease cannot be removed completely

• To palliate pain or slow growth in an unresectable tumour

Preoperative radiation

Preoperative radiation may be considered when:

• The tumour is large

• The tumour is in a complex anatomical location

• Complete surgery appears difficult

• Shrinking or sterilising the peripheral tumour field may improve resectability

Surgery must follow according to the radiation oncologist’s planned timeline.

Postoperative radiation

Postoperative radiation may be recommended when:

• Margins are incomplete

• Margins are close

• Microscopic residual disease is suspected

• The tumour is high-grade

• The tumour has already recurred

• Further wide surgery is not possible

One large retrospective study of cats treated with surgery and electron-beam radiation reported a median survival of approximately 730 days. Cats that had undergone only one surgery before radiation had a lower recurrence risk and a longer disease-free interval than cats that had undergone several previous operations.

Current AAHA guidance gives a broad median survival range of approximately one to two years for cats receiving multimodal treatment involving surgery and radiation, although selected cats live substantially longer.

Radiation without surgery

Radiation can shrink measurable FISS and improve comfort, but radiation alone generally provides poorer local control than surgery combined with radiation.

It may still be useful when:

• Surgery is impossible

• The cat is not a surgical candidate

• The goal is palliation

• The tumour is causing pain or loss of function

Stereotactic radiation and other shorter protocols have produced tumour responses in some cats, but published disease control has generally been limited compared with successful radical surgery.

Does Chemotherapy Help?

Chemotherapy may be considered when:

• The tumour is high-grade

• The mitotic count is high

• Metastasis is present

• The tumour has recurred

• Surgery or radiation cannot achieve complete control

• The oncologist believes systemic risk is significant

Drugs used or studied include:

• Doxorubicin

• Carboplatin

• Epirubicin

• Metronomic chemotherapy protocols

• Other specialist-selected agents

The evidence is mixed.

Some studies have demonstrated tumour responses or encouraging outcomes when chemotherapy was combined with radical surgery. Other studies found no clear improvement in recurrence, metastasis or survival after adding doxorubicin.

Chemotherapy should therefore be presented as an individualised adjunct rather than a guaranteed requirement for every FISS.

What About Electrochemotherapy or Immunotherapy?

Electrochemotherapy combines chemotherapy with electrical pulses that increase drug entry into local tumour cells.

Small studies have reported promising control when electrochemotherapy is used with surgery, but availability is limited and the evidence base is smaller than that for radical surgery and radiation.

A recombinant feline interleukin-2 immunotherapy has also been used in parts of Europe as an adjunct after surgery and radiation. Availability and licensing vary by country, and it is not a replacement for adequate surgical margins.

These options are best discussed with a veterinary oncologist familiar with the specific treatment.

What If the Tumour Cannot Be Removed?

Unresectable disease may be managed with:

• Palliative radiation

• Chemotherapy in selected cases

• Pain relief

• Anti-inflammatory medication when appropriate

• Wound care

• Antibiotics for secondary infection

• Appetite and nutritional support

• Mobility support

• Quality-of-life monitoring

Palliative treatment does not cure the cancer. Its purpose is to reduce pain, slow local progression and maintain comfort.

An ulcerated tumour can develop secondary infection, odour and discharge. Antibiotics may improve these complications but do not treat the sarcoma itself.

What Happens Without Treatment?

FISS usually continues growing and infiltrating local tissues.

Over time it may:

• Invade several muscles

• Attach to or invade bone

• Restrict movement

• Become painful

• Stretch and ulcerate the skin

• Bleed

• Become infected

• Develop necrotic tissue

• Spread to the lungs or other sites

• Make future surgery impossible

There is no reliable rule that every untreated cat will deteriorate within a specific number of months. The speed varies with tumour grade, location and individual biology.

The problem with waiting is not simply that the lump becomes larger. It is that the amount of tissue required for any meaningful treatment increases with it.

What Affects Prognosis?

Important prognostic factors include:

• Whether the first surgery was radical

• Tumour size

• Histological grade

• Mitotic count

• Surgical margins

• Local recurrence

• Metastasis

• Tumour location

• Ability to use radiation

• Overall health of the cat

Current AAHA oncology guidance identifies tumour size of 2 cm or more, a mitotic index above 6, incomplete surgical excision and certain aggressive histological forms as negative prognostic factors.

Features associated with a better outlook

• Small primary tumour

• No previous surgery

• Radical first excision

• Complete histological margins

• Lower-grade disease

• No detectable metastasis

• Distal limb or tail location that permits amputation

• Ability to complete recommended radiation treatment

Features associated with a poorer outlook

• Large tumour

• Interscapular or central trunk location

• Several previous marginal excisions

• Incomplete margins

• High mitotic activity

• Local recurrence

• Lung metastasis

• Invasion of the spine, ribs or body cavity

• Inability to perform radical surgery

Published outcomes vary from a few months in cats with advanced or recurrent disease to several years in cats receiving successful radical treatment.

A median survival figure is not an expiry date. It reflects a group of cats with different tumours, treatments and complications.

What Happens After Surgery?

Recovery depends on the extent of the procedure.

A cat may need:

• Several days of hospitalisation

• Strong pain relief

• Intravenous fluids

• A surgical drain

• An Elizabethan collar

• Restricted activity

• Wound monitoring

• Antibiotics when infection is present

• Nutritional support

• Physiotherapy after major limb or body-wall surgery

• Repeat pathology review

• Radiation planning

Possible surgical complications include:

• Swelling

• Bruising

• Seroma formation

• Infection

• Incision breakdown

• Skin necrosis

• Delayed healing

• Pain

• Reduced appetite

• Temporary or permanent mobility changes

Major complications occurred in a minority of cats undergoing radical 5 cm-margin surgery, including wound dehiscence. The potential morbidity must be balanced against the much greater local-control failure seen after inadequate excision.

How Is Recurrence Monitored?

The surgical site and surrounding tissue should be checked regularly for:

• A new lump

• Deep thickening

• Firmness beneath the scar

• Pain

• Reduced movement

• Skin ulceration

• Swelling

• Discharge

Follow-up may include:

• Physical examination

• Scar and regional tissue palpation

• Chest imaging

• CT or MRI when recurrence is suspected

• Blood testing according to treatment

• Monitoring for radiation or chemotherapy effects

AAHA recommends tailoring oncology rechecks to tumour grade, stage and treatment. High-grade tumours are commonly reassessed every one to three months, while longer intervals may become appropriate later if the cat remains stable.

Recurrence can develop months or years after treatment, so long-term monitoring remains important.

When Is Injection-Site Sarcoma an Emergency?

A small stable lump is not usually an immediate emergency, but it still needs timely investigation when it meets the 3-2-1 rule.

Seek same-day veterinary care if your cat has:

• Rapid tumour enlargement

• Significant pain

• An ulcerated or infected mass

• Repeated bleeding

• Foul discharge

• Reduced appetite

• Marked lethargy

• Difficulty walking

• A surgical wound that is opening

• Swelling that is rapidly worsening after treatment

Go to an emergency veterinary hospital immediately if your cat develops:

• Uncontrolled bleeding

• Collapse

• Severe weakness

• Inability to stand

• Open-mouth breathing

• Marked respiratory effort

• Blue, grey or extremely pale gums

• Severe distress

• Reduced consciousness

These signs may reflect advanced local disease, metastatic disease, blood loss, infection, treatment complications or another unrelated emergency.

What Should You Do Next?

1. Find out exactly when and where the injection was given

Request the veterinary record if necessary.

Record:

• Date

• Product

• Injection site

• Administration route

• When the lump was first noticed

2. Measure the lump

Use a ruler or callipers.

Record:

• Length

• Width

• Approximate depth

• Whether it moves

• Whether it is painful

• Whether the skin is normal

Do not rely on memory. A lump can enlarge gradually enough that the change is difficult to recognise without measurements.

3. Photograph it

Take photographs in the same position and lighting with a ruler beside the lump.

4. Apply the 3-2-1 rule

Arrange biopsy if the lump:

• Persists for three months

• Is larger than 2 cm

• Is increasing one month after the injection

Arrange earlier assessment when the lump is rapidly growing, fixed, painful or ulcerated.

5. Do not ask for a quick lumpectomy

Ask whether the clinic recommends:

• Incisional biopsy

• CT or MRI

• Thoracic staging

• Referral to a surgical oncologist

• Radiation oncology consultation

6. Obtain referral before definitive surgery

A specialist surgeon or oncologist can determine whether treatment may require:

• Radical muscle removal

• Limb amputation

• Hemipelvectomy

• Chest or abdominal wall resection

• Spinal or scapular surgery

• Preoperative radiation

• Postoperative radiation

Referral does not commit you to treatment. It allows you to understand what meaningful treatment would actually involve.

7. Ask for the full pathology report

Important information includes:

• Tumour type

• Grade

• Mitotic count

• Margins

• Lymphovascular invasion

• Necrosis

8. Decide on the treatment goal

The goal may be:

• Cure

• Long-term local control

• Delay of progression

• Relief of pain

• Maintenance of mobility

• Comfort-focused care

A clear goal helps prevent treatment becoming more burdensome than beneficial.

Common Mistakes Owners and Veterinary Teams Should Avoid

Stopping all vaccinations

FISS is rare, while the diseases prevented by vaccination can be common, severe and fatal. Vaccination should be based on individual risk rather than abandoned.

Calling every FISS a vaccine sarcoma

Other injections and chronic inflammatory sites have also been implicated.

Waiting until a lump is visibly large

Tumour size affects the extent of surgery and prognosis.

Treating the 3-2-1 rule as a reason to wait

A rapidly growing or aggressive-looking mass should be assessed before three months.

Relying on a nondiagnostic fine-needle aspirate

A low-cell sample does not exclude sarcoma.

Performing an unplanned excisional biopsy

Removing the lump without adequate margins can compromise definitive treatment.

Assuming a clean pathology margin guarantees cure

Histopathology examines representative sections. Recurrence can still occur after reported complete margins.

Believing radiation or chemotherapy can compensate for inadequate surgery every time

These treatments can improve control but cannot reliably undo an inappropriate first operation.

Assuming non-adjuvanted means risk-free

No injectable feline vaccine has been proven to carry zero FISS risk.

Vaccinating between the shoulder blades

This location can make radical surgery extremely difficult if a sarcoma develops.

Should Cats Still Be Vaccinated?

Yes, when vaccination is indicated.

Feline vaccines protect against serious infectious diseases, and current evidence confirms that FISS remains a rare adverse event. The 2026 pooled estimate was approximately one FISS per 10,000 vaccinations, although the evidence remains imprecise.

The safest approach is not “vaccinate everything every year” or “never vaccinate again”.

It is:

• Assess the cat’s lifestyle and exposure risk

• Use current vaccination guidelines

• Give core vaccines when indicated

• Give non-core vaccines only when risk justifies them

• Avoid unnecessary revaccination

• Select an appropriate formulation

• Use a surgically appropriate location

• Record the exact injection site

• Monitor any resulting lump

Where Should Vaccines Be Given?

Current AAHA/AAFP guidance recommends administering feline vaccines in the lower distal limbs to make radical excision or amputation possible if FISS develops.

Vaccines should not routinely be given:

• Between the shoulder blades

• High on the back

• In a central location where 5 cm margins would be impossible

• In the same undifferentiated area at every visit

Tail vaccination may also be considered, but the injection must be given in the distal tail if future removal with adequate margins is to remain possible.

The exact product, site and route should be documented in the medical record.

Why not use the abdomen to avoid amputation?

Ventral abdominal injections have been proposed because abdominal skin can appear easier to remove.

However, FISS requires two deep fascial planes and 5 cm lateral margins. An abdominal tumour may still require extensive body-wall and abdominal-cavity surgery.

The apparently easier location is not necessarily an easier cancer operation.

Can FISS Be Prevented Completely?

No.

The risk can be reduced, but not eliminated.

Practical measures include:

• Vaccinating according to individual risk

• Avoiding unnecessary injections

• Avoiding routine interscapular injections

• Using distal limb or distal tail sites

• Recording every injection site

• Considering non-adjuvanted or recombinant vaccines when clinically appropriate

• Avoiding repeated injections into the same location

• Selecting non-injectable alternatives when medically equivalent

• Monitoring post-injection lumps

• Following the 3-2-1 rule

• Reporting suspected vaccine adverse events

Decreasing the vaccine volume is not recommended as a prevention strategy because partial dosing may reduce protection without removing the risk of inflammation.

Frequently Asked Questions

Does every vaccine lump turn into cancer?

No. Most temporary vaccine-site swellings are inflammatory and resolve. A lump requires biopsy when it remains for three months, is larger than 2 cm or is increasing one month after vaccination.

Is the 3-2-1 rule still recommended?

Yes. Current feline vaccination guidance continues to recommend the 3-2-1 rule for identifying post-injection masses that need incisional biopsy.

Should a suspicious injection-site lump be removed immediately?

It should be investigated promptly, but not removed as an unplanned lumpectomy. Incisional biopsy, imaging and staging should be coordinated before definitive radical surgery.

Can injection-site sarcoma be cured?

Yes, some cats achieve long-term control or cure after properly planned radical first surgery, particularly when the tumour is small and can be removed with complete margins. Recurrence remains possible even after aggressive treatment.

Are non-adjuvanted vaccines guaranteed to prevent FISS?

No. Some evidence suggests they may carry a lower risk, but current guidelines consider the evidence insufficient to declare one injectable vaccine type universally safest or risk-free.

Final Takeaway

Feline injection-site sarcoma is rare, but it is one of the most locally aggressive cancers encountered in cats.

Most temporary injection-site lumps are not cancer. The ones that require action are identified using the 3-2-1 rule:

• Present after three months

• Larger than 2 cm

• Increasing one month after injection

Once a lump becomes suspicious, the correct response is not a quick excision. It is an incisional biopsy, cross-sectional imaging, metastatic staging and a carefully planned first operation.

That first operation may require 5 cm lateral margins, two deep fascial planes, muscle removal or amputation. It can look aggressive because the cancer itself is aggressive.

Vaccination should continue when medically indicated. The safest strategy is individualised vaccination, distal injection sites, complete medical records and prompt investigation of persistent lumps.

The small lump you investigate properly today is far more treatable than the large recurrent tumour produced by waiting or by attempting an inadequate first removal.

---

If you have found a lump after an injection, are unsure whether it meets the 3-2-1 rule or need help understanding a biopsy, imaging report or treatment plan, ASK A VET™ can help you organise the information and prepare the right questions for your veterinarian.